Figure 6.
Therapeutic Effects of miR-1293 on Tumor Growth In Vivo
(A) The experimental schedule for miR-1293 treatment in nude mice. Tumors were formed by subcutaneous injection of HCT116−/− cells in nude mice. miR-NC or miR-1293 was administered subcutaneously around the tumors for a total of 5 times (3, 7, 10, 14, and 17 days after the injection of cells). (B) Representative images of tumor-bearing nude mice and resected tumors at 19 days after the injection of HCT116−/− cells. Scale bar, 10 mm. (C) Tumor growth curves of xenograft mouse models treated with miR-NC or miR-1293 (n = 10, each). Tumor volume was calculated using the following formula: (shortest diameter) 2 × (longest diameter) × 0.5. Error bar, SD for 10 mice; ∗p < 0.05, ∗∗p < 0.01. (D) Weights of the resected tumors. Tumor weights are shown as a boxplot. Error bar, SD for 10 mice; ∗p < 0.05. (E) Expression analysis of miR-1293 in the resected tumors. The expression level of miR-1293 was measured by qRT-PCR. Each experiment was performed in duplicate. The relative ratio was normalized to the expression of RNU6B. Error bar, SD for 10 mice; ∗∗p < 0.01. (F) Representative images (upper) and evaluation (lower) of immunohistochemical staining for BRD4, APEX1, RPA1, and POLD4 in resected tumors. The density per field was defined using the single point selection tool on the Nikon NIS Elements Br 4.0 software, and the results were normalized to the values of tumors treated with miR-NC (see the Materials and Methods section). Scale bar, 50 μm. ∗∗p < 0.01.